Business
Completion of Acquisition of Compliance Solutions
Completion of Acquisition of Compliance Solutions.
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n \nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n \nAbingdon Health plc\n(\"Abingdon Health\" or \"the Company\")\n \nCompletion of Acquisition of Compliance Solutions\n \nYork, U.K. 15 August 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), is pleased to announce the completion of the acquisition of the CS Lifesciences group (\"Compliance Solutions\"), a consultancy business which specialises in meeting compliance (Quality/ Regulatory/ Clinical) requirements in international IVD and medical device markets.\n \nApplication has been made for the admission to trading on AIM (\"Admission\") for the 9,216,590 new initial Consideration shares (as defined in the announcement dated 24 July 2024). It is expected that Admission will become effective on 19 August 2024.\n \nFollowing the issue of the new 9,216,590 initial Consideration shares the Company will have a total of 189,523,153 Ordinary Shares in issue. The Company does not hold any shares in Treasury.\n \nThe above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \nThe above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.\n \nThe Company intends to launch, shortly, an offer to its retail shareholders at the same price as the recent placing, 9.75p per share.\n \nChris Yates, CEO, commented:\n \n\"We are delighted to welcome Edwin Lindsay and all the Compliance Solutions team to the Abingdon Health group. The acquisition of Compliance Solutions deepens and broadens Ab...